Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome. (Record no. 554)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02281nam a22003257a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 220511s20222022 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1540-4196 |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1089/met.2022.0004 [doi] |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
PMID | 35452324 |
245 ## - TITLE STATEMENT | |
Title | Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome. |
251 ## - Source | |
Source | Metabolic Syndrome & Related Disorders. 2022 Apr 22 |
252 ## - Abbreviated Source | |
Abbreviated source | Metab. syndr. relat. disord.. 2022 Apr 22 |
253 ## - Journal Name | |
Journal name | Metabolic syndrome and related disorders |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Year | 2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Manufacturer | FY2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Publication date | 2022 Apr 22 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
Publication status | aheadofprint |
266 ## - Date added to catalog | |
Date added to catalog | 2022-05-11 |
520 ## - SUMMARY, ETC. | |
Abstract | The introduction of sodium glucose transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus treatment has shown an unexpectedly significant improvement in heart disease outcome trials. Although they have very different modes of action, a portion of the salutary cardiovascular disease improvement may be related to their impact on diabetic dyslipidemia. As discussed in this focused review, the sodium glucose transporter-2 inhibitors as a class show a mild increase in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels, while triglycerides (TG) decrease inconsistently. In particular, the rise in LDL appears to be related to the less atherogenic, large buoyant LDL particles. The glucagon-like peptide-1 receptor agonists show more of an impact on weight loss and improvement in the underlying low HDL and high TG dyslipidemia. The effect of sodium glucose transporter-2 inhibitors and glucagon-like peptide 1 receptor agonists when used in combination remains largely unknown. Also unexplored is difference in effect of these medications among various ethnicities and metabolic syndrome. |
546 ## - LANGUAGE NOTE | |
Language note | English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | IN PROCESS -- NOT YET INDEXED |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME | |
Institution | MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION | |
Department | Medicine/Endocrinology |
657 ## - INDEX TERM--FUNCTION | |
Medline publication type | Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Local Authors | Burman, Kenneth D |
790 ## - Authors | |
All authors | Burman KD, Gandhi S, Naser N, Nylen ES, Premji R, Sen S |
856 ## - ELECTRONIC LOCATION AND ACCESS | |
DOI | <a href="https://dx.doi.org/10.1089/met.2022.0004">https://dx.doi.org/10.1089/met.2022.0004</a> |
Public note | https://dx.doi.org/10.1089/met.2022.0004 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Koha item type | Journal Article |
Item type description | Article |
Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MedStar Authors Catalog | MedStar Authors Catalog | 05/11/2022 | 35452324 | 35452324 | 05/11/2022 | 05/11/2022 | Journal Article |